Net external financial assets decreased to $64 billion in the second quarter of 2026. The Bank of Korea stated that the primary reason for this decline is the evaluation effect due to the rise in domestic stock prices. It is analyzed that the increase in the value of domestic stocks held by foreigners has resulted in an increase in external financial liabilities. Shin Sang-ho, a senior official at the International Department of the Bank of Korea, explained the implications of the decrease in net external financial assets on his blog, stating that net external financial assets, which first exceeded $1 trillion at the end of 2024, have dropped to $64 billion in the second quarter of 2026. The decrease compared to the previous quarter is $689.5 billion, the largest drop since 1994. The Bank of Korea judged that this decline cannot be seen as a weakening of external payment capacity. Shin explained the difference between external financial liabilities and external debts, stating that the increase in the valuation of domestic stocks held by foreigners has overshadowed the current account surplus effect. The current account surplus in the first half of the year increased net external financial assets by $191 billion, but during the same period, the KOSPI rose by 101%. The Bank of Korea emphasized that the rise in stock prices does not guarantee the direction of the index or the flow of funds in the future, and added that net external financial assets, external debts, and the ratio of short-term external debts should be considered together.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.













